The antidiabetic drug teneligliptin induces vasodilation via activation of PKG, Kv channels, and SERCA pumps in aortic smooth muscle

Li, Hongliang; An, Jin Ryeol; Park, Minju; Choi, Jaehee; Heo, Ryeon; Kang, Minji; Mun, Seo‐Yeong; Zhuang, Wenwen; Seo, Mi Seon; Han, Eun‐Taek; Han, Jin‐Hee; Wang, Chun; Park, Won Sun

doi:10.1016/j.ejphar.2022.175305

Cited by 4 publications

(1 citation statement)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Gene-targeted therapy ( 60 ), precision medicine ( 61 ), and personalized therapy ( 62 ) were frequently used in co-cited literature. It is not difficult to see that the current research on RNA methylation in CVD is no longer limited to the simple mechanism study of disease but is committed to the clinical application of research results.…”

Section: Discussionmentioning

confidence: 99%

Bibliometric and visual analysis of RAN methylation in cardiovascular disease

Song

Xie

Lyu

et al. 2023

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

BackgroundRNA methylation is associated with cardiovascular disease (CVD) occurrence and development. The purpose of this study is to visually analyze the results and research trends of global RNA methylation in CVD.MethodsArticles and reviews on RNA methylation in CVD published before 6 November 2022 were searched in the Web of Science Core Collection. Visual and statistical analysis was performed using CiteSpace 1.6.R4 advanced and VOSviewer 1.6.18.ResultsThere were 847 papers from 1,188 institutions and 63 countries/regions. Over approximately 30 years, there was a gradual increase in publications and citations on RNA methylation in CVD. America and China had the highest output (284 and 259 papers, respectively). Nine of the top 20 institutions that published articles were from China, among which Fudan University represented the most. The International Journal of Molecular Sciences was the journal with the most studies. Nature was the most co-cited journal. The most influential writers were Zhang and Wang from China and Mathiyalagan from the United States. After 2015, the primary keywords were cardiac development, heart, promoter methylation, RNA methylation, and N6-methyladenosine. Nuclear RNA, m6A methylation, inhibition, and myocardial infarction were the most common burst keywords from 2020 to the present.ConclusionsA bibliometric analysis reveals research hotspots and trends of RNA methylation in CVD. The regulatory mechanisms of RNA methylation related to CVD and the clinical application of their results, especially m6A methylation, are likely to be the focus of future research.

show abstract

Section: Discussionmentioning

confidence: 99%

Bibliometric and visual analysis of RAN methylation in cardiovascular disease

Song

Xie

Lyu

et al. 2023

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

show abstract

The role of serine/threonine protein kinases in cardiovascular disease and potential therapeutic methods

Wu,

Zou,

Song

et al. 2024

Biomedicine & Pharmacotherapy

View full text Add to dashboard Cite

The sodium-glucose cotransporter 2 inhibitor tofogliflozin induces vasodilation by activating Kv channels, the SERCA pump, and the sGC/cGMP pathway

Zhuang,

Park,

Jeong

et al. 2024

Preprint

View full text Add to dashboard Cite

OBJECTIVE: Tofogliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor widely used to treat T2DM, but it also exhibits cardio-protective effects. This study investigated the vasodilatory action of tofogliflozin using rabbit femoral artery rings pre-contracted with phenylephrine. APPROACH AND RESULTS: The femoral artery quickly separated from the rabbit and fix it to the organ bath chamber. Subsequently, administer an inhibitor that modulates vascular tension in the rings or remove the endothelium to assess its impact on vasodilation. The results showed the concentration-dependent induction of vasodilation by tofogliflozin, a response that remained unchanged following endothelial removal, pretreatment with the nitric oxide synthase (NOS) inhibitor L-NAME, or the inhibition of low- and intermediate-conductance Ca2+-activated K+ channels (SKCa and IKCa) using apamin in combination with TRAM-34. Furthermore, pretreatment with the voltage-dependent K+ (Kv) channel inhibitor 4-AP reduced the vasodilatory effects of tofogliflozin whereas pretreatment with the ATP-sensitive K+ (KATP) channel inhibitor glibenclamide or the large-conductance Ca2+-activated K+ (BKCa) channel inhibitor paxilline did not. Notably, our findings indicated that Kv7.X, rather than Kv1.5 or Kv2.1, is the primary Kv subtype involved in tofogliflozin-induced vasodilation. The vasodilatory effects of tofogliflozin were also significantly inhibited in femoral arterial rings pretreated with the sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) pump inhibitors thapsigargin and cyclopiazonic acid (CPA). Tofogliflozin-induced vasodilation was unaltered in arterial rings exposed to the adenylyl cyclase inhibitor SQ 22536, the protein kinase A (PKA) inhibitor KT 5720, and the protein kinase G (PKG) inhibitor KT 582 whereas it was effectively reduced by the soluble guanylyl cyclase (sGC) inhibitor ODQ. CONCLUSIONS: These findings suggest that tofogliflozin-induced vasodilation is mediated by the activation of the SERCA pump, the sGC/cGMP pathway, and Kv channels, but not the PKA signaling pathway, other K+ channels, or endothelium-dependent mechanisms.

show abstract

The antidiabetic drug teneligliptin induces vasodilation via activation of PKG, Kv channels, and SERCA pumps in aortic smooth muscle

Cited by 4 publications

References 48 publications

Bibliometric and visual analysis of RAN methylation in cardiovascular disease

Bibliometric and visual analysis of RAN methylation in cardiovascular disease

The role of serine/threonine protein kinases in cardiovascular disease and potential therapeutic methods

The sodium-glucose cotransporter 2 inhibitor tofogliflozin induces vasodilation by activating Kv channels, the SERCA pump, and the sGC/cGMP pathway

Contact Info

Product

Resources

About